Måndag 26 Januari | 19:07:06 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Curasight reports encouraging preliminary data from uTREAT Phase I study
2026-01-14 15:28:00

Curasight has announced preliminary data from the first patient dosed in its phase I trial evaluating uTREAT in high-grade gliomas. The results show clear and sustained uptake of the radiopharmaceutical in the tumor, supporting the potential of the company’s uPAR-targeted theranostic platform. BioStock contacted CEO Ulrich Krasilnikoff to get his thoughts on this milestone.

Read the full interview at biostock.se:

Curasight reports encouraging preliminary data from uTREAT Phase I study
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden